UK scientists test experimental drug which could 'significantly improve' health of coronavirus patients

The treatment, known as SNG-001, has been shown to stimulate immune response in the lungs of patients
PA
Ellena Cruse4 May 2020

UK scientists have started testing an experimental Covid-19 drug which they hope will significantly improve the health of coronavirus patients.

The treatment, known as SNG-001, has been shown to stimulate immune response in the lungs of patients with asthma and chronic lung disease during trials.

The procedure uses the naturally occurring protein called interferon-beta which our bodies produce when we get a viral infection.

BBC Panorama gained access to the research at University Hospital Southampton.

Professor Tom Wilkinson, who heads up the drug trial, told the programme: “In an ideal world we would see a significant improvement in the health of the patients receiving the drug, a reduction in those requiring intensive care and ventilation.

“But it is early days to understand that and we will know more when we have the results.”

The drug stimulates immune responses in the lungs
REUTERS

Initial results from the interferon-beta trial at the University of Southampton are expected by the end of June.

The treatment would face further tough checks before it can be used routinely on patients even if the trial is a success.

BBC Panorama: When Will We Be Safe? will air on Monday, May 4 at 7.30pm on BBC One.

Create a FREE account to continue reading

eros

Registration is a free and easy way to support our journalism.

Join our community where you can: comment on stories; sign up to newsletters; enter competitions and access content on our app.

Your email address

Must be at least 6 characters, include an upper and lower case character and a number

You must be at least 18 years old to create an account

* Required fields

Already have an account? SIGN IN

By clicking Sign up you confirm that your data has been entered correctly and you have read and agree to our Terms of use , Cookie policy and Privacy notice .

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Thank you for registering

Please refresh the page or navigate to another page on the site to be automatically logged in